Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux
about
When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transitionCurrent prospects for the fluoroquinolones as first-line tuberculosis therapyTranslating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosisAntituberculosis therapy for 2012 and beyondNovel adjunctive therapies for the treatment of tuberculosisHigh-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosisContribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosisIdentification of new drug targets and resistance mechanisms in Mycobacterium tuberculosisAcquired resistance of Mycobacterium tuberculosis to bedaquilineIn vitro activity of rifampicin and verapamil combination in multidrug-resistant mycobacterium tuberculosisEfflux pump gene expression in multidrug-resistant Mycobacterium tuberculosis clinical isolatesConfinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux MechanismIon Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosisSuppression of Protective Responses upon Activation of L-Type Voltage Gated Calcium Channel in Macrophages during Mycobacterium bovis BCG InfectionEfflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosisRepurposing clinically approved cephalosporins for tuberculosis therapyInterplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosisReduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosisVerapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance.Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy.Disclosure of selective advantages in the "modern" sublineage of the Mycobacterium tuberculosis Beijing genotype family by quantitative proteomicsVerapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis AntibioticsModeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis.Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosisCan the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistanceUpregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosisDraft Genome Sequences of Two Extensively Drug-Resistant Strains of Mycobacterium tuberculosis Belonging to the Euro-American S LineageThe heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis.The role of transport mechanisms in mycobacterium tuberculosis drug resistance and tolerance.Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitorAntimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.Assessment of antibiotic resistance in Klebsiella pneumoniae exposed to sequential in vitro antibiotic treatments.Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux
P2860
Q21145725-F27A8A94-1BF3-474C-9BE6-CCBC7E3A648BQ26823843-0CEC2B03-1C10-4A14-8805-E3EBC4D73CC8Q26824812-C65B1ACE-4A91-4500-BF80-3E31777528D5Q26829101-FE41F800-DCFA-49E0-8E60-5AF09F014CFFQ26829957-51DD8E96-7191-441A-992D-C74921F14D76Q28481039-312AF7CD-D8B8-46E0-837D-5C142CC2BA8BQ28482174-31A445F4-6EB6-4D60-84D0-B5A5C33C5B7DQ28533721-958A3188-2859-4EC3-A607-3AAE2778B540Q28540637-A7990EBA-B095-43F5-9450-030DE7FA7858Q28543447-761E6CF5-7DED-49A5-95D6-D8B1C272BA45Q28543543-180C2E95-603F-4401-A380-16F8B69AE0A5Q28547410-3FA6B5DE-C71A-42E3-AA37-F968B26CE1FFQ28550401-274C2616-A8D6-45AA-A43D-8357AB46AE03Q28554597-B85F249F-98E8-432C-9909-3F55FCFBE1F8Q28659633-0B3DB3DF-EAAF-4614-912C-C8F66A8D3E51Q28828720-90A2580F-22B0-4748-87E9-FCE18317C50CQ33607162-BFC08D78-9A23-46B6-80D0-0BB45D50FAC3Q33798280-666B4306-4193-4E56-8FF9-024A78E14FF6Q33926262-2E34962E-0F90-4BB4-A03E-F2B4E3385E11Q33947806-C74EE9DE-6F95-4CDF-9F8D-797273BE5073Q34070418-4A818AE7-2278-4AF8-B332-3419CBA6E83DQ34298988-6BB75FAE-1800-4092-9C61-B9D29786CB01Q34303366-E82B44AC-0970-4A99-A0F9-8D40FFF7812CQ34923159-1A289C45-B028-469D-81A9-7DAC2AA40D7AQ35125060-EDB60335-3E0B-4720-9B09-AAF3AC101B64Q35242238-BFEE9A48-55E7-4D34-97D8-BB9D35802E33Q36056408-94C82C34-C51C-4A95-9108-AB1B20DE265FQ36070976-25201E4F-7D51-4398-80E1-DFC2B47827F3Q36086373-79E23ACB-C9F6-405D-9AC5-0B9E317BC998Q36157986-398A32D2-8142-45A5-BF66-1CFB132D2E19Q36172383-9D8E7F2D-A459-4161-AD56-63103CE87374Q36397155-04E6E012-34DA-4958-88EC-948227375DB3Q36650094-357ED787-CF5F-4604-829D-7904EACDC6E3Q36675409-B5F144A1-375F-4A84-9DF5-65C96DBC4DB6Q37184072-EFB977E9-1378-4A5E-93A2-5EB123CCDE74Q37277325-325210F6-082C-48A9-BD08-0BA3BD846880Q37307531-7FFDAA94-87A0-44BF-AE6E-A617892F2305Q37385024-9223C15D-A1A6-4940-902E-A47F08E86FB4Q37490975-36D65AE3-B658-4D65-871B-EF50F578B68FQ37679508-98599BFF-6A7C-47C1-9A1A-A382B032CA42
P2860
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Rifampicin reduces susceptibil ...... um tuberculosis through efflux
@en
type
label
Rifampicin reduces susceptibil ...... um tuberculosis through efflux
@en
prefLabel
Rifampicin reduces susceptibil ...... um tuberculosis through efflux
@en
P2093
P2860
P1476
Rifampicin reduces susceptibil ...... um tuberculosis through efflux
@en
P2093
Adelina Jimenez
Christopher R E McEvoy
Gail E Louw
Megan Murray
Melanie Grobbelaar
Paul D van Helden
Rogelio Hernandez-Pando
Rosalba Leon
Thomas C Victor
P2860
P304
P356
10.1164/RCCM.201011-1924OC
P407
P577
2011-04-21T00:00:00Z